EP1722855A1 - Utilisation d'un compose antagoniste d'au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d'une composition pharmaceutique destinee a traiter la rosacee - Google Patents
Utilisation d'un compose antagoniste d'au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d'une composition pharmaceutique destinee a traiter la rosaceeInfo
- Publication number
- EP1722855A1 EP1722855A1 EP05729329A EP05729329A EP1722855A1 EP 1722855 A1 EP1722855 A1 EP 1722855A1 EP 05729329 A EP05729329 A EP 05729329A EP 05729329 A EP05729329 A EP 05729329A EP 1722855 A1 EP1722855 A1 EP 1722855A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- receptor
- use according
- group
- chosen
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000004700 rosacea Diseases 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 102000005962 receptors Human genes 0.000 title claims abstract description 33
- 108020003175 receptors Proteins 0.000 title claims abstract description 33
- 241001303601 Rosacea Species 0.000 title claims abstract description 31
- 239000005557 antagonist Substances 0.000 title claims abstract description 31
- 102000012740 beta Adrenergic Receptors Human genes 0.000 title claims abstract description 24
- 108010079452 beta Adrenergic Receptors Proteins 0.000 title claims abstract description 24
- 108010006590 serotonin 5 receptor Proteins 0.000 title claims abstract description 24
- 102000011392 Galanin receptor Human genes 0.000 title claims abstract description 12
- 108050001605 Galanin receptor Proteins 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 108091005479 5-HT2 receptors Proteins 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims description 41
- 101150059573 AGTR1 gene Proteins 0.000 claims description 22
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- -1 cilexil Chemical compound 0.000 claims description 13
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 13
- 229960000282 metronidazole Drugs 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 7
- 101800002068 Galanin Proteins 0.000 claims description 5
- 102000019432 Galanin Human genes 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003349 gelling agent Substances 0.000 claims description 5
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 230000000149 penetrating effect Effects 0.000 claims description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000002141 anti-parasite Effects 0.000 claims description 3
- 239000003096 antiparasitic agent Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000003352 sequestering agent Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 2
- 229940124091 Keratolytic Drugs 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 229960002122 acebutolol Drugs 0.000 claims description 2
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003266 anti-allergic effect Effects 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 230000001139 anti-pruritic effect Effects 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 229940125687 antiparasitic agent Drugs 0.000 claims description 2
- 239000003908 antipruritic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229940121357 antivirals Drugs 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 229960000932 candesartan Drugs 0.000 claims description 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 229960003745 esmolol Drugs 0.000 claims description 2
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 claims description 2
- 235000004626 essential fatty acids Nutrition 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 229960002198 irbesartan Drugs 0.000 claims description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 2
- 230000001530 keratinolytic effect Effects 0.000 claims description 2
- 239000003410 keratolytic agent Substances 0.000 claims description 2
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 claims description 2
- 229960005417 ketanserin Drugs 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002508 pindolol Drugs 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 229960005187 telmisartan Drugs 0.000 claims description 2
- 150000003568 thioethers Chemical class 0.000 claims description 2
- 229960004605 timolol Drugs 0.000 claims description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 2
- 229960003991 trazodone Drugs 0.000 claims description 2
- 229960004699 valsartan Drugs 0.000 claims description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 229940124641 pain reliever Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 230000027455 binding Effects 0.000 description 13
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 239000003446 ligand Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 206010037888 Rash pustular Diseases 0.000 description 5
- 208000029561 pustule Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 241000193880 Demodex folliculorum Species 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 208000003493 Rhinophyma Diseases 0.000 description 2
- 239000000674 adrenergic antagonist Substances 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 102000016967 beta-1 Adrenergic Receptors Human genes 0.000 description 2
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 2
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- XTJWWTUSMDNKLT-UHFFFAOYSA-N 2-(5-methyl-2-nitro-1h-imidazol-4-yl)ethanol Chemical compound CC=1NC([N+]([O-])=O)=NC=1CCO XTJWWTUSMDNKLT-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 206010047050 Vascular anomaly Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical compound C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000018598 regulation of vasoconstriction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Definitions
- the present invention relates to the field of rosacea treatment.
- the invention aims to provide new pharmaceutical compositions, more particularly dermatological compositions, useful for the treatment of rosacea and comprising, as active agent, an antagonist compound of at least one receptor chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- Rosacea is a common chronic and progressive inflammatory dermatosis linked to5 vascular relaxation. It mainly affects the central part of the face and is characterized by flushing of the face or flushing, facial erythema, papules, pustules, and telangiectasia. In severe cases, especially in men, the soft tissue in the nose can swell and produce a bulbous swelling called rhinophyma. Rosacea usually occurs between the ages of 25 and 70, and is much more common in people fair complexion. It affects more particularly women, although this condition is generally more severe in men. Rosacea is chronic and persists for years with periods of exacerbation and remission.
- Rosacea was originally called "acne rosacea” because its papules (slight raised skin) and inflammatory pustules (scabs of pus) are very similar to those of acne vulgaris. Unlike acne vulgaris, 0 the petiology of which is based on both abnormal keratinization, increased sebum production and bacterial inflammation, inflammation of rosacea is vascular in nature and poorly understood. This facial vascular anomaly results in permanent edema of the dermis which could accompany increased colonization by Demodex folliculorum, a mite which is usually found in the follicles of the face.
- Demodex folliculorum has an etiological role in rosacea (Erbagi et al., 1998, Int J Dermatol, vol.37, pages 421-425; Purcell et al, 1986, J Am Acad Dermatol, vol.15, pages 1159-1162; Sibenge et al., 1992, J Am Acad Dermatol, vol. 26, pages 590-593). It seems that Demodex folliculorum causes or worsens inflammatory reactions, resulting in papules and pustules, by blocking the pilosebaceous follicles of the face (Roihu et al., 1998, J Cutan Pathol, vol.25, pages 550-552 ).
- rosacea The pathogenesis of rosacea is poorly understood. Many factors can be involved without necessarily inducing this condition. These are for example psychological factors, gastrointestinal disorders, environmental factors (exposure to the sun, temperature, humidity) and emotional factors (stress), food (alcohol, spices), hormonal, vascular, or even infection with Helicobacter pilori.
- Rosacea develops in 4 stages, but passing through all stages is not compulsory: - stage 1 of vascular relaxations (around 20 years). Patients have sudden onset of paroxysmal redness of the face and neck, with a feeling of warmth, but without systemic signs. After the attacks, the skin of the face becomes normal again. These "flushes” are triggered by changes in temperature (sometimes leading to thermophobia), the absorption of hot drinks or alcohol. - stage 2 erythematato-telangiectatic (around 30 years). The malar areas are diffusely red. We observe dilated capillaries constituting the classic rosacea. Unlike stage 1, the redness is permanent. In addition to the cheeks, the chin and the middle part of the forehead can be affected.
- stage 3 of papulo-pustules (around 40 years).
- erythema develop papules and pustules a few millimeters in diameter, without associated comedones.
- This dermatosis can be very widespread, sometimes on the glabrous part of the scalp in men, but respects the periphery of the goat and the eyes.
- Patients complain of sensitive skin, with subjective intolerance to most oily topicals and cosmetics.
- - stage 4 of rhinophyma (around 50 years or later). This late phase mainly affects men, unlike the other stages.
- the nose is enlarged, diffusely red and the follicular orifices are dilated.
- the skin gradually thickens.
- Minor forms of rosacea can be treated with active ingredients such as anti-seborrheics and anti-infectives, for example benzoyl peroxide, retinoic acid, metronidazole.
- active ingredients such as anti-seborrheics and anti-infectives, for example benzoyl peroxide, retinoic acid, metronidazole.
- Metronidazole, or (methyl-2-nitro-5-imidazolyl) -2- ethanol is known in the prior art for its antibacterial, antiparasitic and antiprotozoal properties. It exerts a selective toxicity with respect to anaerobic microorganisms as well as hypoxic cells. At the level of the latter, metronidazole is reduced to derivatives capable of altering the DNA structure of these cells.
- the work of the Applicant has made it possible to demonstrate the usefulness of the receptor antagonist compounds chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin in the treatment of rosacea.
- Beta-adrenergic receptors are involved in the regulation of various physiological functions, such as metabolic activity, cardiac activity, respiration, central nervous system activity, blood pressure and vascular tone.
- the 5-HT2 receptors the 5-HT5 receptors belong to the family of serotonin (5-HT) receptors. All of the 5-HT receptors are coupled to G proteins, except 5-HT3 which is an ion channel. Activation of 5-HT2 receptors stimulates the activity of phospholipase C.
- the transduction system of 5-HT5 receptors is positively associated with adenylate cyclase.
- the AT1 receptor is involved in the regulation of vasoconstriction by angiotensin II.
- angiotensin II increases the tone of the subcutaneous arteries.
- Galanine is a peptide of 29 amino acids found in the central nervous system. According to certain studies, galanine has a role in the modulation of the cutaneous vascular reaction and in inflammation (Pincelli, 1990, Br J Dermatol, vol. 122, pages 745-750).
- the work of the Applicant has made it possible to demonstrate the involvement of beta-adrenergic receptor antagonists, of the AT1 receptor, of the 5-HT2 receptor, of the 5-HT5 receptor, and of the galanin receptor in the treatment of rosacea .
- This activity has been demonstrated by the use of metronidazole which results in an interaction with beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor. More specifically, it has been found that the use of metronidazole inhibits the binding of natural ligands to these receptors.
- the invention aims to offer a new method of treating rosacea consisting in administering to a subject suffering from rosacea an effective amount of an antagonist compound of at least one receptor chosen from the group comprising beta-adrenergic receptors , the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
- the invention relates more particularly to the use of an antagonist compound of at least one receptor chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor , and the galanin receptor, for the preparation of a pharmaceutical composition for the treatment of rosacea.
- the invention also relates to the use of a compound antagonist of two receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanine, for the preparation of a pharmaceutical composition defined as above.
- the invention also relates to the use of a compound antagonist of three receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanine for the preparation of a pharmaceutical composition defined as above.
- the invention also relates to the use of an antagonist compound of four receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanine for the preparation of a pharmaceutical composition defined as above.
- the invention also relates to the use of an antagonist compound of five receptors chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanine for the preparation of a pharmaceutical composition defined as previously.
- antagonist compound is meant according to the present invention, any molecule which inhibits the binding of at least one agonist or a natural ligand to its receptor.
- beta-adrenergic receptor antagonist compounds By way of nonlimiting examples of beta-adrenergic receptor antagonist compounds, mention may be made of metropobol, esmolol, acebutolol, timolol, pindolol and labetolol.
- composition which is the subject of the present invention is a dermatological composition, for topical administration on the skin.
- rosacea treatment is understood to mean, according to the present invention, the treatment and / or prevention of rosacea, in one or more of the stages described above.
- the composition is intended for the treatment of the first stage of rosacea.
- the composition is intended for the treatment of the second stage of rosacea.
- the composition is intended for the treatment of the third stage of rosacea.
- the composition is intended for the treatment of the fourth stage of rosacea.
- the composition contains 0.0001 to 20% by weight, preferably from 0.1 to 2%, and more preferentially of the order of 0.75 to 1% of an antagonist such as defined above.
- the present invention relates, in addition to the use of an antagonist as defined above, the use of derivatives thereof.
- derivatives means compounds which are distinguished from the antagonist as defined above by substitution, addition or deletion of one or more chemical groups.
- compositions of the invention comprise, in addition to the antagonist as defined above, at least one other therapeutic agent capable of increasing the effectiveness of the treatment.
- at least one other therapeutic agent capable of increasing the effectiveness of the treatment.
- antibiotics antibacterials, antivirals, antiparasitics, antifungals, anesthetics, analgesics, antiallergics, retinoids, anti-free radicals, antipruritics, keratolytics, antiseborrheics, antihistamines, sulfides, immunosuppressive or antiproliferative products.
- the antagonist compound is not metronidazole.
- the composition of the present invention also contains metronidazole.
- the invention also relates to a method of identifying an antagonist compound of at least one receptor chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor: a) bringing the specific radiolabelled ligand into contact with the recombinant human protein of each receptor in a sample; b) bringing the radiolabelled specific ligand and the excess non-radiolabelled specific ligand into contact with the recombinant human protein of each receptor in another sample; c) Addition of the compound to be tested in the two samples; d) Measurement of radioactivity by counting the scintillation in the two samples; e) Calculation of the difference in radioactivity measured in the two samples; f) Selection of said compounds for which a reduction in radioactivity is obtained in step e) relative to the control value obtained with the receptors not brought into contact with the compound to be tested.
- compositions of the invention may also comprise any additive usually used in the pharmaceutical, dermatological field, compatible with the antagonist as defined above. Mention may in particular be made of sequestrants, antioxidants, sun filters, preservatives, for example DL-alpha-tocopherol, fillers, electrolytes, humectants, dyes, bases or common acids, inorganic or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA, soothing and protective agents for the skin such as pallantoin, skin penetrating agents, gelling.
- sequestrants for example DL-alpha-tocopherol
- fillers electrolytes, humectants, dyes, bases or common acids, inorganic or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA, soothing and protective agents for the skin such as pallanto
- additives can be present in the composition in an amount of 0 to 20% by weight relative to the total weight of the composition.
- sequestering agents examples include ethylenediaminetetraacetic acid (EDTA), as well as its derivatives or its salts, dihydroxyethylglycine, citric acid, tartaric acid, or mixtures thereof.
- EDTA ethylenediaminetetraacetic acid
- preservatives examples include benzalkonium chloride, phenoxyethanol, benzyl alcohol, diazolidinylurea, parabens, or mixtures thereof.
- humectants examples include glycerin and sorbitol.
- compositions of the invention may contain one or more penetrating agents in preferential concentrations ranging from 0 to 20% and more preferably ranging from 0.6 to 3% by weight relative to the total weight of the composition.
- penetrating agents use is preferably made, without this list being limiting, of compounds such as propylene glycol, dipropylene glycol, propylene glycol dipelargonate, lauroglycol, ethoxydiglycol.
- compositions according to the invention may also contain one or more surfactants in preferential concentrations ranging from 0 to 10% and more preferably ranging from 0.1 to 2%.
- compositions of the present invention may be in all the galenical forms normally used for topical application, in particular in the form of aqueous, hydroalcoholic or oily solutions, of lotion-type dispersions, of aqueous, anhydrous or lipophilic gels, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or of suspensions or emulsions of consistency soft, semi-liquid or solid of the cream, gel or ointment type or else micro-emulsions, micro-capsules, micro-particles or vesicular dispersions of ionic and / or non-ionic type.
- the creams can be formulated from a mixture of mineral oil, or a mixture of beeswax and water which instantly emulsifies, in which the antagonist compound as defined above is added, dissolved in a small amount of oil such as almond oil.
- the ointments can be formulated by mixing a solution of said antagonist in an oil such as almond oil in heated paraffin, then allowing the mixture to cool.
- compositions according to the invention mention may be made of those comprising an active phase containing (expressed as a percentage by weight):
- - 0 to 90% preferably 5 to 25%, especially 10 to 20%, of water; - 0 to 10%, preferably 0 to 2%, especially 0 to 0.5%, of surfactant;
- aqueous phase comprising a gelling agent, and water.
- the aqueous phase of a composition according to the invention in the form of an emulsion may comprise water, floral water such as blueberry water, or natural thermal or mineral water, for example chosen from Vittel water, Vichy basin water, Uriage water, Roche Posay water, Bourboule water, Enghien-les-Bains water, Saint Gervais-les-Bains, water from Néris- les-Bains, water from Allevard-les-Bains, water from Digne, water from Maizines, water from Neyrac-les-Bains, water from Lons-le-Saunier, Eaux Bonnes, water from Rochefort, water from Saint Christau, water from Fumades and water from Tercis-les-bains, water from Avène or Aix les Bains water.
- Said aqueous phase may be present at a content of between 10 and 90% by weight relative to the total weight of the composition, preferably between 20 and 80% by weight.
- gelling agents of the polyacrylamide family such as the Sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80 mixture sold under the name Simulgel 600 by the company Seppic, the polyacrylamide / isoparaffin C13-14 / laureth-7 mixture such as, for example, that sold under the name Sepigel 305 by the company Seppic, the family of acrylic polymers coupled to hydrophobic chains such as PEG-150 / decyl / SMDI copolymer sold under the name of Aculyn 44 (polycondensate comprising at least as elements, a polyethylene glycol containing 150 or 180 moles of ethylene oxide, decyl alcohol and methylene bis (4-cyclohexylisocyanate) (SMDI), 35% by weight in a mixture of propylene glycol (39%) and water (26%)), the family of modified starches such as modified potato starch sold under the
- the gelling agent as described above can be used at preferential concentrations ranging from 0.1 to 15% and, more preferably, ranging from 0.5 to 5%.
- the gels can preferably be prepared by dispersing or dissolving the metronidaole in an appropriate ratio, in a gel of the carbomer, poloxamer or cellulosic type.
- metronidazole as a receptor antagonist chosen from the group comprising beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5 receptor -HT5, and the galanin receptor.
- Example 1 Measurement of the binding to beta-1 and beta-2 adrenergic receptors, AT1. 5-HT fi ⁇ . 5-HT ? A and galanine
- beta-1 and beta-2 adrenergic receptor binding test was carried out according to the method described by Smith and Generaler 1999, Cardiovasc Drug Ther, vol. 13, pages 123-126.
- the AT1 receptor binding test was carried out according to the method described by Bergsma et al, 1992, Biochem Biophys Res Comm, vol. 183, pages 989-995.
- the 5-HT 5A receptor binding test was carried out according to the method described by Ress et al, 1994, FEBS Lett, vol. 355, pages 242-246.
- the 5-HT 2A receptor binding test was carried out according to the method described by Bonhauss et al, 1995, Brit J Pharmacol, vol. 1155, pages 622-628.
- the galanin receptor binding test was carried out according to the method described by Sullivanet al, 1997, Biochem Biophys Res Comm, vol. 233, pages 823-828.
- the binding of metronidazole to each receptor was determined by competitive experiments.
- the receptor a recombinant human protein, was incubated according to the times indicated in Table 1 below, with a single concentration of labeled specific ligand, in the presence of metronidazole at 10 ⁇ M. Bound radioactivity was measured by scintillation counting. Table 1
- the specific binding of the ligand to the receptor is defined as the difference between the total binding and the non-specific binding determined in the presence of an excess of unlabeled ligand.
- Metronidazole therefore inhibits binding to beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor, and the galanin receptor.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0401715A FR2866567A1 (fr) | 2004-02-20 | 2004-02-20 | Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee |
PCT/FR2005/000367 WO2005089871A1 (fr) | 2004-02-20 | 2005-02-17 | Utilisation d’un compose antagoniste d’au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d’une composition pharmaceutique destinee a traiter la rosacee |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1722855A1 true EP1722855A1 (fr) | 2006-11-22 |
Family
ID=34833940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05729329A Withdrawn EP1722855A1 (fr) | 2004-02-20 | 2005-02-17 | Utilisation d'un compose antagoniste d'au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d'une composition pharmaceutique destinee a traiter la rosacee |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070275978A1 (fr) |
EP (1) | EP1722855A1 (fr) |
CA (1) | CA2553208A1 (fr) |
FR (1) | FR2866567A1 (fr) |
WO (1) | WO2005089871A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201990041A1 (ru) * | 2016-06-16 | 2019-05-31 | Альмиралль, С.А. | Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении |
JP2019518045A (ja) * | 2016-06-16 | 2019-06-27 | アルミラル・ソシエダッド・アノニマAlmirall, S.A. | チモロール及び抗炎症剤を含む組成物 |
WO2022007878A1 (fr) * | 2020-07-10 | 2022-01-13 | 长庚医疗财团法人林口长庚纪念医院 | UTILISATION D'UN ANTAGONISTE DE L'ADRÉNORÉCEPTEUR β-1 POUR LA PRÉPARATION D'UNE COMPOSITION DE RÉDUCTION DES LÉSIONS DES CELLULES ÉPITHÉLIALES INDUITES PAR L'INHIBITEUR DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE ET D'INHIBITION DES CELLULES CANCÉREUSES |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05502217A (ja) * | 1989-08-21 | 1993-04-22 | ベス イスラエル ホスピタル アソシエーション | セロトニン拮抗薬の局所用調製物を使用した、皮膚、眼、および粘膜の過敏症、炎症、および過増殖状態の治療のための方法および組成物 |
FR2758263B1 (fr) * | 1997-01-16 | 1999-12-17 | Oreal | Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue |
WO2000029009A1 (fr) * | 1998-11-18 | 2000-05-25 | Coastside Bio Resources | Peptides presentant une activite anticancereuse et anti-inflammatoire |
AU1618901A (en) * | 1999-11-18 | 2001-05-30 | John D. Bolla | Treatment of rosacea |
-
2004
- 2004-02-20 FR FR0401715A patent/FR2866567A1/fr active Pending
-
2005
- 2005-02-17 CA CA002553208A patent/CA2553208A1/fr not_active Abandoned
- 2005-02-17 EP EP05729329A patent/EP1722855A1/fr not_active Withdrawn
- 2005-02-17 WO PCT/FR2005/000367 patent/WO2005089871A1/fr not_active Application Discontinuation
- 2005-02-17 US US10/590,077 patent/US20070275978A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2005089871A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2553208A1 (fr) | 2005-09-29 |
WO2005089871A1 (fr) | 2005-09-29 |
FR2866567A1 (fr) | 2005-08-26 |
US20070275978A1 (en) | 2007-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2886850A1 (fr) | Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee | |
EP1722855A1 (fr) | Utilisation d'un compose antagoniste d'au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d'une composition pharmaceutique destinee a traiter la rosacee | |
EP1791598A1 (fr) | Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee | |
EP1718285A2 (fr) | Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee | |
WO2005089750A2 (fr) | Utilisation du metronidazole pour le traitement des pathologies liees au recepteur de type b de l’interleukine 8 et/ou recepteur de type 1 de pacap | |
EP1732542A2 (fr) | Utilisation du metronidazole pour le traitement d'un desordre de la vascularisaton cutanee | |
EP1686975A1 (fr) | UTILISATION DU FEPRADINOL POUR LA PREPARATION D’UNE COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE LA ROSACEE | |
EP1686978B1 (fr) | Utilisation de l'idrocilamide pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee | |
WO2005079786A1 (fr) | Utilisation d’un compose modifiant la secretion de l’interleukine 5, de l’interleukine 6 et/ou de l’interleukine 10 pour la preparation d’une composition pharmaceutique destinee a traiter la rosacee | |
WO2005089751A2 (fr) | Utilisation du metronidazole pour le traitement d’une inflammation cutanee | |
FR2862539A1 (fr) | Utilisation du piketoprofen pour la fabrication d'une composition pharmaceutique pour le traitement de la rosacee | |
FR2899475A1 (fr) | Composition pharmaceutique pour le traitement de la rosacee | |
MXPA06009315A (es) | Uso de metronidazol para el tratamiento de un trastorno de la vascularizacion cutanea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060920 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: LV |
|
17Q | First examination report despatched |
Effective date: 20070420 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GALDERMA RESEARCH & DEVELOPMENT |
|
RAX | Requested extension states of the european patent have changed |
Extension state: LV Payment date: 20060920 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070831 |